By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to its HS-20093, a B7-H3-targeted antibody drug conjugate (ADC), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver gene negative progression or recurrence after platinum-based chemotherapy.
HS-20093: Development and Recognition
HS-20093 is under investigation in multiple studies across lung cancer, sarcoma, head and neck cancer, and other solid tumors in China. The NMPA previously awarded BTD to HS-20093 for extensive stage small cell lung cancer (ES-SCLC) following standard first-line treatment in November last year. In February this year, the drug received another BTD for osteosarcoma progressing after at least second-line treatment.
Clinical Implications
The BTD underscores the potential of HS-20093 to address significant unmet medical needs in oncology. By targeting B7-H3, HS-20093 offers a novel therapeutic approach for patients with limited treatment options following platinum-based chemotherapy.-Fineline Info & Tech